[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiation-oncology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiation-oncology":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,75,100,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100599440","phase-3-hypofractionated-vs-conventional-rt-after-prosthetic-breast-reconstruction-100599440",false,"NCT07084519","Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction","Randomized Controlled Trial of Postmastectomy Hypofractionated Radiotherapy Versus Conventional Fractionated Radiotherapy in Breast Cancer Patients Undergoing Prosthetic Breast Reconstruction","Inclusion Criteria:\n\n* Female, aged 18-75 years\n* Karnofsky Performance Status ≥60\n* Histopathologically confirmed invasive breast adenocarcinoma\n* Total mastectomy \\[with or without nipple-areolar complex preservation\\] + axillary dissection\u002Fsentinel lymph node biopsy + implant\u002Fexpander placement R0 resection with negative margins\n* pT3 or N2-3 disease; or pT1-2N1\n* No distant metastasis\n* Completed standard neoadjuvant\u002Fadjuvant chemotherapy cycles\n* ≤8 weeks post-chemotherapy or ≤12 weeks post-surgery if no chemotherapy\n* Signed informed consent\n\nExclusion Criteria:\n\n* Prior radiotherapy to chest wall or nodal regions\n* Pregnancy or lactation\n* T4 stage disease\n* Autologous breast reconstruction of the irradiated breast\n* Pre-radiotherapy local\u002Fregional\u002Fdistant metastasis\n* Grade ≥3 implant-related adverse events irreversible before radiotherapy\n* Bilateral breast cancer requiring bilateral radiotherapy\n* Concurrent\u002Fsecondary malignancy with disease-free interval \\\u003C5 years \\[except non-melanoma skin cancer, papillary\u002Ffollicular thyroid cancer, or cervical carcinoma in situ\\]\n* Active collagen vascular disease, e.g., SLE, scleroderma\n* Uncontrolled comorbidities: acute cardiovascular disease, substance abuse, or psychiatric disorders","FEMALE","18 Years","75 Years",{"count":20,"type":21},506,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study investigates the safety and efficacy of hypofractionated radiotherapy (HFRT) versus conventional fractionated radiotherapy (CFRT) in breast cancer patients undergoing total mastectomy with prosthetic reconstruction.\n\nStudy Design Population: Patients with high-risk breast cancer after mastectomy and immediate implant reconstruction.\n\nIntervention:\n\nHFRT Arm: 43.5 Gy in 15 fractions (2.9 Gy\u002Ffraction, 3 weeks). Control Arm: CFRT (50 Gy in 25 fractions, 2 Gy\u002Ffraction, 5 weeks). Endpoints Primary: Reconstruction failure rate (e.g., implant removal, capsular contracture)",[27,28,29],"Breast Cancer","Breast Reconstruction","Radiation Oncology",[31,32,33],"breast cancer","prosthetic breast reconstruction","hypofractionated radiotherapy","RECRUITING","2026-06-17",{"date":37,"type":38},"2026-06-22","ACTUAL",{"date":40,"type":38},"2026-03-27",{"date":42,"type":21},"2030-12-31",{"name":44,"class":45},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100640978","higher-radiation-dose-to-the-tumor-may-help-avoid-surgery-in-rectal-cancer-patients-100640978","NCT07616297","Higher Radiation Dose to the Tumor May Help Avoid Surgery in Rectal Cancer Patients","REctal Organ Preservation With a BOost Approach Using CBCT-based Online Adaptive radioTherapy","REBOOT","Inclusion Criteria:\n\n* Age ≥18 years\n* Eastern cooperative oncology group (ECOG) performance status ≤2\n* Histologically confirmed rectal adenocarcinoma\n* Non-locally advanced rectal cancer, defined as (magnetic resonance imaging (MRI)-based) T1-3, N0\u002FN1 (≤3 positive mesorectal lymph nodes), MX\u002FM0\n* Indication for curative treatment with organ preservation\n* Discussed in the multidisciplinary tumor board (MTB)\n* Written informed consent\n\nExclusion Criteria:\n\n* Previous radiotherapy in the pelvic area\n* Other malignancies, except for adequately treated basal cell carcinoma (BCC), at time of inclusion or within 3 years prior to inclusion\n* Contra-indications for (chemo)radiotherapy or surgery\n* Presence of lateral lymph nodes, cN2 status, extramural vascular invasion (EMVI) or mesorectal fascia involvement as seen on MRI\n* Mucinous defined tumor on MRI\n* Prior local excision of the primary tumor\n* DPD (dihydropyrimidine dehydrogenase) deficiency\n* Unable to understand the requirements of the study and to give written informed consent, as determined by the treating physician","ALL",{"count":57,"type":21},25,[59],"NA","The goal of this prospective study is to evaluate if a higher radiation dose to the tumor can increase the organ preservation rate in non-locally advanced rectal cancer.",[62,29],"Rectal Cancer",[29,64,65],"Rectal cancer","Organ Preservation","2026-05-29",{"date":68,"type":38},"2026-06-01",{"date":70,"type":38},"2026-01-27",{"date":72,"type":21},"2030-08-01",{"name":74,"class":45},"Claudia Schuurhuizen",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":55,"minAge":4,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":46},"100524982","radiation-treatment-plan-evaluation-learning-tool-pilot-project-100524982","NCT06115811","Radiation Treatment Plan Evaluation Learning Tool Pilot Project","Development and Assessment of a Novel, Systematic Radiation Treatment Plan Evaluation Learning Tool for Radiation Oncology Residents","Inclusion Criteria:\n\n* The pilot program will be open to radiation oncology resident physicians that are in their PGY-2, PGY-3, or PGY-4 year.\n* All residents must have completed a breast cancer-specific radiation oncology rotation at least 3 months prior to enrollment in the pilot program in order to be eligible.\n\nExclusion Criteria:\n\n-The study will not include any special populations.",true,{"count":84,"type":21},20,[59],"This study involves both the development of a novel learning tool, the Radiation Treatment Plan Evaluation Learning Module, as well as a pilot program to validate this tool as an effective resource to teach treatment plan review and optimization to radiation oncology residents.",[29],[29,89],"Education","NOT_YET_RECRUITING","2026-05-20",{"date":93,"type":38},"2026-05-22",{"date":95,"type":21},"2026-06-15",{"date":97,"type":21},"2029-07-01",{"name":99,"class":45},"Massachusetts General Hospital",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":55,"minAge":17,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":46},"100342158","postoperative-radiotherapy-in-thoracic-esophageal-squamous-cell-carcinoma-with-neoadjuvant-chemoradiotherapy-100342158","NCT03734952","Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy","Prospective Randomized Controlled Trial of Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy","Inclusion Criteria:\n\n1. Patients must not have received any prior anticancer therapy Histologically-confirmed squamous cell carcinoma of the esophagus;\n2. Tumors of the esophagus are located in the thoracic cavity;\n3. Pre-treatment stageⅡ-Ⅲ (AJCC\u002FUICC 8th Edition)\n4. Male or non pregnant female\n5. Age is between 18 years and 65 years,\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 or Karnofsky performance status (KPS) of 70 or more;\n7. Adequate bone marrow function (White Blood Cells ≥4x109 \u002FL; Neutrophil ≥1.5×109 \u002FL; Hemoglobin≥ 90 g\u002FL; platelets≥100x109 \u002FL);\n8. Adequate liver function (Total bilirubin, Aspartate transaminase(AST) and Alanine transaminase (ALT) ≤2x Upper Level of Normal (ULN));\n9. Adequate renal function (serum creatinine (SCr) ≤1.5 x ULN);\n10. The patient has provided written informed consent and is able to understand and comply with the study.\n\nExclusion Criteria:\n\n1. Patients with non-squamous cell carcinoma histology;\n2. Patients with advanced inoperable or metastatic esophageal cancer;\n3. Patients with another previous or current malignant disease；\n4. Any patient with a significant medical condition which is thought unlikely to tolerate the therapies. Such as cardiac disease;\n5. Age \\>65 years;\n6. Pregnant or lactating female or people during the birth-period who refused to take contraceptives;\n7. Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior;\n8. Patients who refuse surgery after neoadjuvant chemotherapy;\n9. Unsuitable to be enrolled in the trial in the opinion of the investigators","65 Years",{"count":109,"type":21},537,[59],"The primary objective is to compare surgery with postoperative radiotherapy (PORT) versus surgery, in terms of the overall survival time (OS) in Stage II or III squamous cell esophageal carcinoma with neoadjuvant chemoradiotherapy(nCRT).",[29],"2023-09-22",{"date":115,"type":38},"2023-09-25",{"date":117,"type":38},"2023-05-01",{"date":119,"type":21},"2029-01-01",{"name":121,"class":45},"Fujian Medical University Union Hospital",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":55,"minAge":17,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":46},"100321558","short-course-radiotherapy-56gy7gy8gy-followed-by-neo-adjuvant-chemotherapy-for-locally-advanced-rectal-cancer-100321558","NCT03466424","Short-course Radiotherapy (5×6Gy\u002F7Gy\u002F8Gy) Followed by Neo-adjuvant Chemotherapy for Locally Advanced Rectal Cancer","Phase I Trial of Dose-escalation Preoperative Short-course Radiotherapy (5×6Gy\u002F7Gy\u002F8Gy) Followed by Neo-adjuvant Chemotherapy in Locally Advanced Rectal Cancer : the FJUHR-01 Trial","Inclusion Criteria:\n\n* Previously untreated, biopsy-proven stage T3-4 and\u002For N+，resectable rectal adenocarcinoma with the tumors near anal verge within 12 cm;\n* Male or non-pregnant female;\n* Between 18 and 70 years of age;\n* Adequate hematologic function: white blood cell(WBC) counts≥4,000\u002Fmm3, neutrophils counts ≥ 1,500\u002Fmm3, platelet counts ≥ 100,000\u002FµL, hemoglobin ≥ 9g\u002FL;\n* Adequate renal function: creatinine ≤ 1.5×upper normal limit;\n* Adequate hepatic function: total bilirubin, glutamic oxalacetic transaminase, glutamate pyruvate transaminase level \\\u003C 2.0×upper normal limit);\n* Satisfactory performance status: Karnofsky Performance Status(KPS)≥70;\n* Approval from the ethics committee and prior written informed consents from all patients before registration were obtained.\n\nExclusion Criteria:\n\n* the evidence of relapse or distant metastasis;\n* receiving treatment of other anti-cancer drugs or methods;\n* Patients have low compliance and are not able to complete the entire trial;\n* the presence of uncontrolled life-threatening diseases;\n* dysfunction of heart, brain, lung and et al.","70 Years",{"count":131,"type":21},9,"OBSERVATIONAL","Preoperative radiotherapy followed by total mesorectal excision (TME) has been recommended as the preferred treatment method for locally advanced rectal cancer. Similar rates of local control, survival and toxicity were observed in preoperative long-course radiotherapy (LCRT) (45-50.4 Gy in 25-28 fractions) and short-course radiotherapy (SCRT) of 25 Gy in five fractions. For the convenience of SCRT, a growing number of patients tend to receive SCRT as preoperative radiotherapy. Although SCRT can shorten treatment interval and cut down the cost of treatment, it's pathological complete response (pCR) rate is relatively low (SCRT vs. LCRT: 0.7% vs. 16%). Hence, the optimal pattern of preoperative therapy of locally advanced rectal cancer still deserves to be explored. Previous studies have confirmed the feasibility and safety of 30Gy\u002F5 fractions in SCRT of rectal cancer and verified that SCRT followed by mFOLFOX6 chemotherapy can improve the pCR rates. Therefore, investigators aimed to establish a dose escalation mode of SCRT (5×6Gy\u002F7Gy\u002F8Gy) followed by four cycles of modified FOLFOX6(mFOLFOX6) chemotherapy to test the safety and efficacy in treating locally advanced rectal cancer.",[29,62],[136,137,138,139,140,141],"Short-course radiotherapy","dose escalation","neo-adjuvant chemotherapy","mFOLFOX6","rectal cancer","Phase I trial","2023-02-14",{"date":144,"type":38},"2023-02-16",{"date":146,"type":38},"2022-08-01",{"date":148,"type":21},"2026-12-01",{"name":121,"class":45}]